Dr. John Cush RheumNow
5 years 5 months ago
#RNL2021 coverage from @doctorRBC
"Biosimilars are on their way. Coming to you in 2024! They will most likely be cheaper for insurance companies, but will they be cheaper for patients? " #RheumNow
Dr. John Cush RheumNow
5 years 5 months ago
Join us for Tuesday Night Rheumatology with Dr. Philip Robinson and Dr. Iain McInness. We'll discuss highlight sessions for RheumNow Live 2021 #RNL2021
https://t.co/oJ4xYL32aC https://t.co/Eix01GlWoj
In the current issue of Annals of Rheumatic Disease, Dr. Peggy Crow honors the life and career of one the great, historic rheumatologists of all time: Dr. Charles Christian. For those interested in the history of rheumatology, mentoring and leadership, this is a good read. For those interested in leading a truly good life, and being a real role model, this is a must read.
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: New, Improved Therapy for Pompe Disease
https://t.co/dEZ9Y0biHu https://t.co/rXh7fH13rc
Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).
k dao KDAO2011
5 years 5 months ago
Dr. R Fleischmann "Don't be afraid to use TOFA!"
FDA warnings on⬆️ MACE/malign based on 1 study (Pfizer 1133) in high risk patients.
Older age, tobacco use are risks for MACE/CV events and cancer.
Meta-analyses, registries, clinical trials program do NOT show⬆️ risk
#RNL2021 https://t.co/4p9YqyDrGz
Dr. John Cush RheumNow
5 years 5 months ago
Randomized trial of 206 adults with knee OA found that a web-based exercise intervention supported by text messaging improved knee pain and function at 24 weeks vs web-based information alone. (MCID pain 72.1% vs 42%) https://t.co/h5UaedS4Zm
Dr. John Cush RheumNow
5 years 5 months ago
Not in the US, but biosimilar infliximab (CT-P13) is being used subcutaneously in the EU and Canada. Analysis of 2 RCTs shows (compared to IV inflectra or remicade) SC CT-P13 greater DAS28-CRP, CDAI and SDAI response rates. https://t.co/prSVJ0BIdd
Dr. John Cush RheumNow
5 years 5 months ago
Have you had the chance to listen to the latest RheumNow podcast on combination biologics?
https://t.co/FFtYHhw7Qc https://t.co/YT1h8iL647
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Planes, Trains and COVID Distancing
MMWR reports the risk of acquiring an infection with SARS-CoV-2 is reduced 23% to 57% when the middle seat was vacant (compared with full aircraft occupancy).
https://t.co/tGs9Go7DhU https://t.co/Gz9L1ERcUU
Dr. John Cush RheumNow
5 years 5 months ago
News Feature: Autoimmune Risk of Death Up during COVID
A population-based study in the UK shows patients with RAIRD were 44% more likely to die during the '20 COVID-19 pandemic (Mar - Apr) compared to either the general population or their pre-COVID risk.
https://t.co/e1vWOjGglt https://t.co/OIaM3Hx7BO
Dr. John Cush RheumNow
5 years 5 months ago
Scoot over small molecule inhibitors, the future might be with nanoparticle targeting for RA! Dr. Fleischmann reviews study on nanoparticle targeting of CCP Ab that showed noninferiority to Tocilizumab #RNL2021 coverage from @KDAO2011
Dr. John Cush RheumNow
5 years 5 months ago
BRAND NEW PODCAST-- Combination Biologics
We talk about the articles featured on RheumNow this week.
https://t.co/FFtYHhNJeM https://t.co/XCFMsZ6ttG
Dr. John Cush RheumNow
5 years 5 months ago
#RNL2021 Coverage from Dr. Rachel Tate @uptoTate
The good and the bad of HLA B27 iritis from Dr. Wang #RNL2021
-- 90% of patient maintain 20/40 vision or better with treatment
-- BUT disease can relapse and can alternate between eyes
Dr. John Cush RheumNow
5 years 5 months ago
Johns Hopkins myositis clinic: anti-mitochondrial Abs (AMA) found in 5% adult myositis, 1% of juv. myositis pts. AMA assoc. w/ severe muscle weakness, Raynauds, dysphagia, cardiomyopathy & treatment refractory Dz - Screening for cardiac & swallowing https://t.co/oj9kwHgTHf
